Clinical Trials Logo

Chronic Urticaria clinical trials

View clinical trials related to Chronic Urticaria.

Filter by:

NCT ID: NCT06455202 Not yet recruiting - Clinical trials for Chronic Spontaneous Urticaria

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

EMBARQ-CSU2
Start date: July 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.

NCT ID: NCT06445023 Not yet recruiting - Clinical trials for Chronic Spontaneous Urticaria

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

EMBARQ-CSU1
Start date: July 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.

NCT ID: NCT06396026 Not yet recruiting - Clinical trials for Chronic Spontaneous Urticaria

A Study of Efficacy and Safety of TLL-018 in CSU Participants

Start date: May 30, 2024
Phase: Phase 3
Study type: Interventional

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria (CSU) With Inadequate Controll to Second Generation H1-antihistamines.

NCT ID: NCT06365879 Not yet recruiting - Clinical trials for Chronic Spontaneous Urticaria

To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria

Start date: May 1, 2024
Phase: Phase 3
Study type: Interventional

This study is a multicenter, randomized, double-blind, positive parallel controlled phase III clinical trial to compare efficacy, immunogenicity, pharmacokinetics, pharmacodynamics and safety of omalizumab α(CMAB007) and Xolair® in patients with refractory chronic spontaneous urticaria

NCT ID: NCT06295302 Recruiting - Clinical trials for Chronic Spontaneous Urticaria

A Study to Explore the Efficacy and Safety of HWH486 in Adults With Chronic Spontaneous Urticaria

Start date: December 13, 2023
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-bind and placebo-controlled phase IIa dose-finding study to assess the safety and efficacy of HWH486 in adults with chronic spontaneous urticaria (CSU). In addition, the pharmacokinetic characteristics will also be investigated.

NCT ID: NCT06294288 Active, not recruiting - Clinical trials for Chronic Spontaneous Urticaria

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants

Start date: July 1, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-003 and Part 2, multiple ascending dose (MAD).

NCT ID: NCT06268470 Active, not recruiting - Chronic Urticaria Clinical Trials

Antiplatelet Therapy in Chronic Urticaria

Start date: June 1, 2018
Phase: Phase 2
Study type: Interventional

This study compares the combination of antiplatelets and antihistamine versus antihistamine alone for the treatment of chronic spontaneous urticaria

NCT ID: NCT06250400 Not yet recruiting - Clinical trials for Chronic Spontaneous Urticaria

Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)

Start date: March 31, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to study patients with chronic spontaneous urticaria. The main question it aims to answer is the efficacy and safety of histamine human immunoglobulin (ShuYangMinNing) in the treatment of chronic spontaneous urticaria.

NCT ID: NCT06228560 Recruiting - Clinical trials for Chronic Spontaneous Urticaria

Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Start date: January 25, 2024
Phase: Phase 2
Study type: Interventional

The study is a Phase II, multicenter, randomized, double-blind study to evaluatethe efficacy and safety of LP-003 administered subcutaneously as an add-on therapy for the treatment of adult patients aged 18-75 who have been diagnosed with refractory CSU and who remain symptomatic despitestandard-dose H1 antihistamine treatment.

NCT ID: NCT06162728 Recruiting - Clinical trials for Chronic Spontaneous Urticaria

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

BEACON
Start date: November 29, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, and other pharmacodynamic (PD) parameters (such as effects on mast cells (MC), serum tryptase levels, and on allergic skin reactivity) will be investigated.